New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
07:44 EDTXOM, CVX, BP, TOT, RDS.ATotal warns of 'inaccurate pricing' in energy benchmarks, FT reports
Total Oil Trading SA, the trading arm of Total (TOT), stated in a letter to international regulators that “several times a year, estimates of market prices on key indices ... are out of line with our experience of the day” and "consequently deform the real price levels paid at every level of the price chain, including by the consumer,” according to Financial Times. Reference Link
News For A;BP;XOM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 22, 2015
10:21 EDTXOMExxon Mobil says media reports on Iran sanctions lobbying inaccurate
Subscribe for More Information
09:57 EDTBPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:00 EDTBPBP upgraded to Neutral on reduced Russia risk at JPMorgan
JPMorgan upgraded BP (BP) to Neutral citing less risk in Russia and a pathway to cash flow neutrality in 2017. JPMorgan this morning also upgraded Total (TOT) to Overweight and Eni SpA (E) to Neutral.
05:32 EDTBPBP upgraded to Neutral from Underweight at JPMorgan
May 21, 2015
07:25 EDTBPUBS to hold a conference
Subscribe for More Information
May 20, 2015
17:04 EDTBPBP to pay Transocean $125M in compensation for legal fees
Subscribe for More Information
17:03 EDTBPTransocean reaches settlement agreements with BP, PSC
Subscribe for More Information
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
15:01 EDTBPHalliburton reaches agreement with BP to resolve remaining issues
Subscribe for More Information
13:15 EDTXOMExxon Mobil announces significant oil discovery offshore Guyana
Exxon Mobil announced a significant oil discovery on the Stabroek Block, located approximately 120 miles offshore Guyana. The well was drilled by ExxonMobil affiliate, Esso Exploration and Production Guyana Ltd., and encountered more than 295 feet of high-quality oil-bearing sandstone reservoirs. It was safely drilled to 17,825 feet in 5,719 feet of water. Stabroek Block is 6.6M acres. The well was spud on March 5. The well data will be analyzed in the coming months to better determine the full resource potential. Esso Exploration and Production Guyana Ltd. holds 45% interest. Hess Guyana Exploration Limited holds 30% interest and CNOOC Nexen Petroleum Guyana Limited holds 25% interest.
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTBPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:12 EDTBPBP downgraded to Sell from Neutral at Goldman
Goldman downgraded BP to Sell based on limited upstream growth, a slowdown in asset disposals, and ongoing overhang from Macondo.
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTXOM, BPEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use